Animal models of fibrotic lung disease

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 2, 2013, Pages 167-179

  Moore, Bethany B ^a   Lawson, William E ^c,d   Oury, Tim D ^e   Sisson, Thomas H ^a   Raghavendran, Krishnan ^b   Hogaboam, Cory M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Collagen; Cytokines; Fibroblast; Fibrosis

Indexed keywords

ADENOVIRUS VECTOR; ADVANCED GLYCATION END PRODUCT; ASBESTOS; BLEOMYCIN; CYTOKINE; DIPHTHERIA TOXIN; DOXYCYCLINE; FLUORESCEIN ISOTHIOCYANATE; INTERLEUKIN 13; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MUTANT PROTEIN; SILICON DIOXIDE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN C; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AGING; ANIMAL MODEL; ASBESTOSIS; AUTOSOMAL DOMINANT INHERITANCE; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CELL DAMAGE; CELL INTERACTION; DIABETES MELLITUS; DISEASE COURSE; DISEASE PREDISPOSITION; ENDOPLASMIC RETICULUM STRESS; FIBROSING ALVEOLITIS; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC DISORDER; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HYPERPLASIA; INFLAMMATION; INJURY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG CONTUSION; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; LUNG INJURY; MORTALITY; NONHUMAN; OCCUPATIONAL EXPOSURE; OCULAR ALBINISM; OXIDATIVE STRESS; PATHOGENESIS; PROMOTER REGION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RADIATION; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; UPREGULATION; WHOLE BODY RADIATION; WILD TYPE;

ANIMALS; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; GENETIC DISEASES, INBORN; HUMANS; LUNG DISEASES, INTERSTITIAL; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY MUCOSA;

EID: 84883192594     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0094TR     Document Type: Review

References (117)

1. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165: 277-304.
2. Coultas D, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994;150: 967-972.
3. Flaherty KR, Thwaite EL, Kazerooni EA, Gross BH, Toews GB, Colby TV, Travis WD, Mumford JA, Murray S, Flint A, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58: 143-148.
4. Monaghan H,Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004;125: 522-526.
5. Perez A, Rogers R, Dauber J. The prognosis of idopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29:S19-S26.
6. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164: 1722-1727.
7. Katzenstein AL, Zisman DA, Litzky LA, Nguyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol 2002;26: 1567-1577.
8. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med 2000;161: 646-664.
9. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L152-L160.
10. Cohn LA, Norris CR, Hawkins EC, Dye JA, Johnson CA, Williams KJ. Identification and characterization of an idiopathic pulmonary fibrosis-like condition in cats. J Vet Intern Med 2004;18: 632-641.
11. Williams KJ, Maes R, Del Piero F, Lim A, Wise A, Bolin DC, Caswell J, Jackson C, Robinson NE, Derksen F, et al. Equine multinodular pulmonary fibrosis: a newly recognized herpesvirus-associated fibrotic lung disease. Vet Pathol 2007;44: 849-862.
12. Webb JA, Armstrong J. Chronic idiopathic pulmonary fibrosis in a West Highland white terrier. Can Vet J 2002;43: 703-705.
13. Kishimoto T, Kato K, Arakawa H, Ashizawa K, Inai K, Takeshima Y. Clinical, radiological, and pathological investigation of asbestosis. Int J Environ Res Public Health 2012;8: 899-912.
14. Roggli VL, Gibbs AR, Attanoos R, Churg A, Popper H, Cagle P, Corrin B, Franks TJ, Galateau-Salle F, Galvin J, et al. Pathology of asbestosis: an update of the diagnostic criteria: report of the Asbestosis Committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med 2010;134: 462-480.
15. Sanchez VC, Pietruska JR, Miselis NR, Hurt RH, Kane AB. Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos? Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1: 511-529.
16. Oberdorster G. Significance of particle parameters in the evaluation of exposure-dose-response relationships of inhaled particles. Inhal Toxicol 1996;8: 73-89.
17. Davis GS, Leslie KO, Hemenway DR. Silicosis in mice: effects of dose, time, and genetic strain. J Environ Pathol Toxicol Oncol 1998;17: 81-97.
18. Barbarin V, Nihoul A, Misson P, Arras M, Delos M, Leclercq I, Lison D, Huaux F. The role of pro- and anti-inflammatory responses in silica-induced lung fibrosis. Respir Res 2005;6:112.
19. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, Williams JP, Sime PJ. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse when compared to intratracheal instillation. Exp Lung Res 2006; 32: 181-199.
20. Ohtsuka Y, Wang XT, Saito J, Ishida T, Munakata M. Genetic linkage analysis of pulmonary fibrotic response to silica in mice. Eur Respir J 2006;28: 1013-1019.
21. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, Carter AB, Rothman PB, Flavell RA, Sutterwala FS. The NALP3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008;105: 9035-9040.
22. Degryse AL, Lawson WE. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci 2011;341: 444-449.
23. Muggia FM, Louie AC, Sikic BI. Pulmonary toxicity of antitumor agents. Cancer Treat Rev 1983;10: 221-243.
24. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008;40: 362-382.
25. Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol 1974;77: 185-197.
26. Lawson WE, Polosukhin VV, Stathopoulos GT, Zoia O, Han W, Lane KB, Li B, Donnelly EF, Holburn GE, Lewis KG, et al. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am J Pathol 2005;167: 1267-1277.
27. Lawson WE, Polosukhin VV, Zoia O, Stathopoulos GT, Han W, Plieth D, Loyd JE, Neilson EG, Blackwell TS. Characterization of fibroblast-specific protein 1 in pulmonary fibrosis. Am J Respir Crit Care Med 2005;171: 899-907.
28. Moore BB, Kolodsick JE, Thannickal VJ, Cooke K, Moore TA, Hogaboam C, Wilke CA, Toews GB. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005;166: 675-684.
29. Aoki Y, Kojo Y, Yamada S, Onoue S. Respirable dry powder formulation of bleomycin for developing a pulmonary fibrosis animal model. J Pharm Sci 2012;101: 2074-2081.
30. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Blackwell TS, Lawson WE. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010;299:18.
31. Adamson IY. Pulmonary toxicity of bleomycin. Environ Health Perspect 1976;16: 119-126.
32. Lawson WE, Loyd JE. The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease? Proc Am Thorac Soc 2006;3: 345-349.
33. Rydell-Tormanen K, Andreasson K, Hesselstrand R, Risteli J, Heinegard D, Saxne T, Westergren-Thorsson G. Extracellular matrix alterations and acute inflammation; developing in parallel during early induction of pulmonary fibrosis. Lab Invest 2012;92: 917-925.
34. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171: 1279-1285.
35. Goldstein RH, Lucey EC, Franzblau C, Snider GL. Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis 1979;120: 67-73.
36. Starcher BC, Kuhn C, Overton JE. Increased elastin and collagen content in the lungs of hamsters receiving an intratracheal injection of bleomycin. Am Rev Respir Dis 1978;117: 299-305.
37. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 1979;95: 117-130.
38. Gharaee-Kermani M, Hatano K, Nozaki Y, Phan SH. Gender-based differences in bleomycin-induced pulmonary fibrosis. Am J Pathol 2005;166: 1593-1606.
39. Phan SH, Armstrong G, Sulavik MC, Schrier D, Johnson KJ, Ward PA. A comparative study of pulmonary fibrosis induced by bleomycin and an O2 metabolite producing enzyme system. Chest 1983;83: 44S-45S.
40. Roberts SN,Howie SE,WallaceWA, BrownDM, Lamb D, Ramage EA, Donaldson K. A novel model for human interstitial lung disease: hapten-driven lung fibrosis in rodents. J Pathol 1995; 176: 309-318.
41. Moore B, Paine R III, Christensen P, Moore T, Sitterding S, Ngan R, Wilke C, Kuziel W, Toews G. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol 2001;167: 4368-4377.
42. Christensen P, Goodman R, Pastoriza L, Moore B, Toews G. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell dependent. Am J Pathol 1999;155: 1773-1779.
43. Kolodsick JE, Toews GB, Jakubzick C, Hogaboam C, Moore TA, McKenzie A, Wilke CA, Chrisman CJ, Moore BB. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004;172: 4068-4076.
44. Moore BB, Murray L, Das A, Wilke CA, Herrygers AB, Toews GB. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol 2006;35: 175-181.
45. Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, Guidot D, Rojas M, Roman J. Predisposition for disrepair in the aged lung. Am J Med Sci 2012;344: 41-51.
46. Redente EF, Jacobsen KM, Solomon JJ, Lara AR, Faubel S, Keith RC, Henson PM, Downey GP, Riches DW. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 2011;311:L510-L518.
47. Xu J, Gonzalez ET, Iyer SS, Mac V, Mora AL, Sutliff RL, Reed A, Brigham KL, Kelly P, Rojas M. Use of senescence-accelerated mouse model in bleomycin-induced lung injury suggests that bone marrow-derived cells can alter the outcome of lung injury in aged mice. J Gerontol A Biol Sci Med Sci 2009;64: 731-739.
48. Englert JM, Hanford LE, Kaminski N, Tobolewski JM, Tan RJ, Fattman CL, Ramsgaard L, Richards TJ, Loutaev I, Nawroth PP, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008;172: 583-591.
49. Samuel CS, Zhao C, Bathgate RA, Bond CP, Burton MD, Parry LJ, Summers RJ, Tang ML, Amento EP, Tregear GW. Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J 2003;17: 121-123.
50. Wang L, Lyerla T. Histochemical and cellular changes accompanying the appearance of lung fibrosis in an experimental mouse model for Hermansky Pudlak syndrome. Histochem Cell Biol 2010;134: 205-213.
51. Naik P, Horowitz JC, Moore TA, Wilke CA, Toews GB, Moore BB. Pulmonary fibrosis induced by G-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-b. J Gerontol A Biol Sci Med Sci 2012;303:L1046- L1056.
52. Torres-Gonzalez E, Bueno M, Tanaka A, Krug LT, Cheng DS, Polosukhin VV, Sorescu D, Lawson WE, Blackwell TS, Rojas M, et al. Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am J Respir Cell Mol Biol 2012;46: 748-756.
53. McMillan T, Moore B, Weinberg J, Vannella K, Fields W, Christensen P, van Dyk L, Toews G. Exacerbation of established pulmonary fibrosis in a murine model by gamma herpesvirus. Am J Respir Crit Care Med 2008;177: 771-780.
54. Vannella KM, Luckhardt TR, Wilke CA, van Dyk LF, Toews GB, Moore BB. Latent herpesvirus infection augments experimental pulmonary fibrosis. Am J Respir Crit Care Med 2009;181: 465-477.
55. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995;50: 1234-1239.
56. Stewart JP, Egan JJ, Ross AJ, Kelly BG, Lok SS, Hasleton PS, Woodcock AA. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999;159: 1336-1341.
57. Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000;55: 958-961.
58. Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA Jr, Loyd JE, Stecenko AA. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003;41: 2633-2640.
59. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in THY-1(2) lung fibroblasts. Am J Respir Cell Mol Biol 2007;2007: 226-235.
60. Muro AF, Moretti FA, Moore BB, Yan M, Atrasz RG, Wilke CA, Flaherty KR, Martinez FJ, Tsui JL, Sheppard D, et al. An essential role for fibronectin extra Type III domain A in pulmonary fibrosis. Am J Respir Crit CareMed 2008;177: 638-645.
61. Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 1513;9: 111-116.
62. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997;100: 768-776.
63. Lee CG, Cho SJ, Kang MJ, Chapoval SP, Lee PJ, Noble PW, Yehualaeshet T, Lu B, Flavell RA, Milbrandt J, et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med 2004; 200: 377-389.
64. Kolb M, Bonniaud P, Galt T, Sime PJ, Kelly MM, Margetts PJ, Gauldie J. Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" And "fibrosis-resistant" mouse strains. Am J Respir Cell Mol Biol 2002;27: 141-150.
65. Pulichino AM, Wang IM, Caron A, Mortimer J, Auger A, Boie Y, Elias JA, Kartono A, Xu L, Menetski J, et al. Identification of transforming growth factor beta1-driven genetic programs of acute lung fibrosis. Am J Respir Cell Mol Biol 2008;39: 324-336.
66. Baughman RP, Lower EE, Miller MA, Bejarano PA, Heffelfinger SC. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16: 57-61.
67. Hardie WD, Korfhagen TR, Sartor MA, Prestridge A, Medvedovic M, Le Cras TD, Ikegami M, Wesselkamper SC, Davidson C, Dietsch M, et al. Genomic profile of matrix and vasculature remodeling in TGFalpha induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 2007: 309-321.
68. Korfhagen TR, Swantz RJ, Wert SE, McCarty JM, Kerlakian CB, Glasser SW, Whitsett JA. Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice. J Clin Invest 1994;93: 1691-1699.
69. Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S, Hardie WD. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. Am J Respir Cell Mol Biol 2012;46: 380-388.
70. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001;194: 809-821.
71. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107: 1529-1536.
72. Sime PJ, Marr RA, Gauldie D, Xing Z, Hewlett BR, Graham FL, Gauldie J. Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol 1998;153: 825-832.
73. Fujita M, Shannon JM, Morikawa O, Gauldie J, Hara N, Mason RJ. Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Am J Respir Cell Mol Biol 2003;29: 669-676.
74. Thomas AQ, Lane K, Phillips J III, PrinceM, Markin C, Speer M, Schwartz DA, Gaddipati R, Marney A, Johnson J, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002;165: 1322-1328.
75. Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001;344: 573-579.
76. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympany P, Thomas AQ, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004;59: 977-980.
77. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, DiMaio JM, Kinch LN, Grishin NV, Garcia CK. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009;84: 52-59.
78. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA III, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356: 1317-1326.
79. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104: 7552-7557.
80. van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, van Es HW, van den Bosch JM, Grutters JC. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010;182: 1419-1425.
81. Marshall RP, Puddicombe A, Cookson WO, Laurent GJ. Adult familial cryptogenic fibrosing alveolitis in the UK. Thorax 2000; 55: 143-146.
82. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342.
83. Lawson WE, Loyd JE, Degryse AL. Genetics in pulmonary fibrosis: familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis. Am J Med Sci 2011;341: 439-443.
84. Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, Burch LH, Wahidi MM, Phillips JA III, Sporn TA, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005;172: 1146-1152.
85. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, et al. A common Muc5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011;364: 1503-1512.
86. Wei ML. Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res 2006;19: 19-42.
87. Young LR, Pasula R, Gulleman PM, Deutsch GH, McCormack FX. Susceptibility of Hermansky-Pudlak mice to bleomycin-induced Type II cell apoptosis and fibrosis. Am J Respir Cell Mol Biol 2007;37: 67-74.
88. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, Xu XC, Newcomb DC, Jones BR, Roldan J, Lane KB, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011;108: 10562-10567.
89. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M, Lang G, Fink L, Bohle RM, Seeger W, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178: 838-846.
90. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008;105: 13051-13056.
91. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, Garcia CK. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008;178: 729-737.
92. Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA. Pneumonitis and emphysema in Sp-C gene targeted mice. J Biol Chem 2003;278: 14291-14298.
93. Goto H, Ledford JG, Mukherjee S, Noble PW, Williams KL, Wright Jr. M. The role of surfactant protein A in bleomycin-induced acute lung injury. Am J Respir Crit Care Med 2010;181: 1336-1344.
94. Degryse AL, Xu XC, Newman JL, Mitchell DB, Tanjore H, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Phillips JA III, et al. Telomerase deficiency does not alter bleomycin-induced fibrosis in mice. Exp Lung Res 2012;38: 124-134.
95. Liu T, Chung MJ, Ullenbruch M, Yu H, Jin H, Hu B, Choi YY, Ishikawa F, Phan SH. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest 2007;117: 3800-3809.
96. Young LR, Gulleman PM, Bridges JP, Weaver TE, Deutsch GH, Blackwell TS, McCormack FX. The alveolar epithelium determines susceptibility to lung fibrosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med 2012;186: 1014-1024.
97. Sisson TH, Mendez M, Choi K, Subbotina N, Courey A, Cunningham A, Dave A, Engelhardt JF, Liu X,White ES, et al. Targeted injury of Type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010;181: 254-263.
98. Osterholzer JJ, Christensen PJ, Lama V, Horowitz JC, Hattori N, Subbotina N, Cunningham A, Lin Y, Murdock BJ, Morey RE, et al. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following Type II alveolar epithelial cell injury. J Pathol 2012;228: 170-180.
99. Bull TM, Clark B, McFann K, MossM. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med 2010;182: 1123-1128.
100. ARDS-Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome: the Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342: 1301-1308.
101. Knight PR, Davidson BA, Nader ND, Helinski JD, Marschke CJ, Russo TA, Hutson AD, Notter RH, Holm BA. Progressive, severe lung injury secondary to the interaction of insults in gastric aspiration. Exp Lung Res 2004;30: 535-557.
102. Raghavendran K, Davidson BA, Helinski JD, Marshcke CJ, Manderscheid PA, Woytash JA, Notter RH, Knight PR. A rat model for isolated bilateral lung contusion from blunt chest trauma. Anesth Analg 2005;101: 1482-1489.
103. Christensen TG, Lucey EC, Breuer R, Snider GL. Acid-induced secretory cell metaplasia in hamster bronchi. Environ Res 1988;45: 78-90.
104. Patel BV, Wilson MR, Takata M. Resolution of acute lung injury and inflammation: a translational mouse model. Eur Respir J 2012;39: 1162-1170.
105. Raghavendran K, Davidson BA, Mullan BA, Manderscheid PA, Russo T, Hutson AD, Holm BA, Notter RH, Knight PR. Acid and particulate induced aspiration injury in mice: role of MCP-1. Am J Physiol Lung Cell Mol Physiol 2005;289:L134-L143.
106. Karvonen RL, Fernandez-Madrid F, Maughan RL, Palmer KC, Fernandez-Madrid I. An animal model of pulmonary radiation fibrosis with biochemical, physiologic, immunologic, and morphologic observations. Radiat Res 1987;111: 68-80.
107. McDonald S, Rubin P, Chang AY, Penney DP, Finkelstein JN, Grossberg S, Feins R, Gregory PK. Pulmonary changes induced by combined mouse beta-interferon (RMUIFN-beta) and irradiation in normal mice: toxic versus protective effects. Radiother Oncol 1993;26: 212-218.
108. Haston CK, Travis EL. Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res 1997;57: 5286-5291.
109. Johnston CJ, Wright TW, Rubin P, Finkelstein JN. Alterations in the expression of chemokine mRNA levels in fibrosis-resistant and -sensitive mice after thoracic irradiation. Exp Lung Res 1998;24: 321-337.
110. Ghobadi G, Bartelds B, van der Veen SJ, Dickinson MG, Brandenburg S, Berger RM, Langendijk JA, Coppes RP, van Luijk P. Lung irradiation induces pulmonary vascular remodelling resembling pulmonary arterial hypertension. Thorax 2012;67: 334-341.
111. Epperly MW, Guo H, Gretton JE, Greenberger JS. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol 2003;29: 213-224.
112. Raghavendran K, Davidson BA, Woytash JA, Helinski JD, Marschke CJ, Manderscheid PA, Notter RH, Knight PR. The evolution of isolated bilateral lung contusion from blunt chest trauma in rats: cellular and cytokine responses. Shock 2005;24: 132-138.
113. Hoth JJ, Hudson WP, Brownlee NA, Yoza BK, Hiltbold EM, Meredith JW, McCall CE. Toll-like receptor 2 participates in the response to lung injury in a murine model of pulmonary contusion. Shock 2007; 28: 447-452.
114. Pierce EM, Carpenter K, Jakubzick C, Kunkel SL, Flaherty KR, Martinez FJ, Hogaboam CM. Therapeutic targeting of CC ligand 21 or CC chemokine receptor 7 abrogates pulmonary fibrosis induced by the adoptive transfer of human pulmonary fibroblasts to immunodeficient mice. Am J Pathol 2007;170: 1152-1164.
115. Trujillo G, Meneghin A, Flaherty KR, Sholl LM, Myers JL, Kazerooni EA, Gross BH, Oak SR, Coelho AL, Evanoff H, et al. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci Transl Med 2010;2:57ra82.
116. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007;7: 118-130.
117. Martin-Mosquero C, Peces-Barba G, Rubio ML, Ortega M, Rodriguez- Nieto MJ, Martinez Galan L, Gonzalez-Mangado N. Increased collagen deposition correlated with lung destruction in human emphysema. Histol Histopathol 2006;21: 823-828.